Yeast-based vaccines as immunotherapy

Details Yeast-based vaccines as immunotherapy Yeast-based vaccines as immunotherapy

2008-12-15

2011-11-29

Aeder, Sean (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

08067559

ABSTRACT:
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed.

REFERENCES:
patent: 4320194 (1982-03-01), Bull
patent: 4725550 (1988-02-01), Perucho et al.
patent: 4775622 (1988-10-01), Hitzeman et al.
patent: 4871838 (1989-10-01), Bos et al.
patent: 5310654 (1994-05-01), Isberg et al.
patent: 5413914 (1995-05-01), Franzusoff
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5744144 (1998-04-01), Finn et al.
patent: 5830463 (1998-11-01), Duke et al.
patent: 5847095 (1998-12-01), Bos et al.
patent: 5858378 (1999-01-01), Bostwick
patent: 5919651 (1999-07-01), Hitzeman et al.
patent: 5961978 (1999-10-01), Gaudernack et al.
patent: 6090546 (2000-07-01), Breivik et al.
patent: 6107457 (2000-08-01), Arlinghaus et al.
patent: 6187307 (2001-02-01), Cohen
patent: 6482407 (2002-11-01), Soo Hoo
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6759046 (2004-07-01), Gaudernack et al.
patent: 6861057 (2005-03-01), Gaudernack et al.
patent: 6923958 (2005-08-01), Xiang et al.
patent: 7083787 (2006-08-01), Duke et al.
patent: 7439042 (2008-10-01), Duke et al.
patent: 7465454 (2008-12-01), Franzusoff et al.
patent: 2002/0044948 (2002-04-01), Khleif et al.
patent: 2002/0155108 (2002-10-01), Barbera-Guillem
patent: 2003/0035810 (2003-02-01), Caplan
patent: 2004/0072759 (2004-04-01), Gaudernack et al.
patent: 2004/0171796 (2004-09-01), Schlom et al.
patent: 2005/0074849 (2005-04-01), Gaudernack et al.
patent: 2007/0048860 (2007-03-01), Schlom et al.
patent: 2007/0166323 (2007-07-01), Duke et al.
patent: 2007/0172503 (2007-07-01), Selitrennikoff et al.
patent: 2007/0224208 (2007-09-01), Guo et al.
patent: 2008/0003239 (2008-01-01), Duke et al.
patent: 2008/0069831 (2008-03-01), Duke et al.
patent: 2008/0069833 (2008-03-01), Franzusoff et al.
patent: 2008/0107671 (2008-05-01), Duke et al.
patent: 2009/0074805 (2009-03-01), Duke et al.
patent: 2009/0304741 (2009-12-01), Duke et al.
patent: 2010/0034840 (2010-02-01), Apelian et al.
patent: 2010/0104604 (2010-04-01), Selitrennikoff et al.
patent: 2010/0111912 (2010-05-01), Apelian et al.
patent: 0414404 (1991-02-01), None
patent: 2486400 (1982-01-01), None
patent: 04-506298 (1992-11-01), None
patent: 10-510246 (1998-10-01), None
patent: WO 91/00356 (1991-01-01), None
patent: WO 92/14756 (1992-09-01), None
patent: WO 94/04171 (1994-03-01), None
patent: WO 97/40156 (1997-10-01), None
patent: WO 00/66153 (2000-11-01), None
patent: WO 01/29233 (2001-04-01), None
patent: WO 01/82963 (2001-11-01), None
patent: WO 02/39951 (2002-05-01), None
Fenton et al (Journal of the National Cancer Institute, 1995, 87(24): 1853-1861).
Lemoine et al (Oncogene, 1989, 4(2): Abstract).
Fenton et al (Journal of the National Cancer Institute, 1995, 87(24): 1853-1861).
Velders et al (The Journal of Immunology, 2001, 166:5366-5373).
Lemoine et al (Oncogene, 1989, 4(2): 159-164).
U.S. Appl. No. 12/334,729, filed Dec. 15, 2008, Franzusoff et al.
U.S. Appl. No. 12/334,775, filed Dec. 15, 2008, Franzusoff et al.
Ben-Efraim, S. (Tumor Biology 1999; 20: 1-24).
Bodey et al. (Anticancer Research 2000; 20: 2665-2676).
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).
Frazer, I. (Expert. Opin. Pharmacother. 2004; 5: 2427-2434).
Granziero et al. (Eur. J. Immunol. 1999, 29: 1127-1138).
Marincola et al. (TRENDS in Immunology 2003;24:334-341).
North (Adv. Immunol 1984; 35: 89-155).
Rosenberg et al. (The New England Journal of Cancer 2004; 350: 1461-1463).
Schlegel et al. (Journal of Neuro-Oncology 1992; 14: 93-100).
Adams et al. International Reviews of Immunology, vol. 11 No. 2, pp. 133-141 (1994).
Allsopp et al., European Journal of Immunology, vol. 26 No. 8, pp. 1951-1959 (1996).
Bachmann et al., 1994, Curr. Op. Immunol., 6:320-326.
Baker et al., 1988, Cell, 54:335-344.
Bizzini et al., 1990, FEMS Microbiol. Immunol., 64:155-168.
Bourdette et al., 1994, J. Immunol., 152:2510-2519.
Brake et al., 1984, Proc. Natl. Acad. Sci. USA, 81:4642-4646.
Brossier et al., Infection and Immunity, vol. 67, No. 2, Feb. 1999, pp. 964-967.
Brown, D., 1995, The Washington Post, “Gene Therapy ‘Oversold’ by Researchers, Journalists”.
Chou et al., 1994, J. Immunol., 152:2520-2529.
Coghlan, 1995, New Scientists, 145:14-15.
Cohen, 1994, Science, 264:1660.
Cohen, 1994, Science, 264:1839.
Davies et al., 1992, Nucleic Acids Res., 20(11):2693-2698.
Demmer et al., 1993, J. Immunol., 150(12):5371-5378.
Engelhardt et al., 1994, Hum. Gene Ther, 5:1217-1229.
Fattal-German et al., 1992, Develop. Biol. Standard., 77:115-120.
Franzusoff et al., 1995, J. Biol. Chem., 270(7):3154-3159.
Fujita et al., 1987, Bulletin of the World Health Organization, 65(3):303-308.
Garber et al., AIDS Reviews, vol. 5 No. 3, pp. 131-139 (2003).
Gnirke et al., 1991, EMBO J., 10(7):1629-1634.
Gobin et al., 1995, Gene, 163:27-33.
Hatsuyama et al., 1994, Plant Cell Physiol., 35(1):93-98.
Kaur et al., Topics in HIV Medicine, vol. 11 No. 3, pp. 76-85 (2003).
Ketner et al., 1994, Proc. Natl. Acad. Sci. USA, 91:6186-6190.
Layton et al. Immunology, vol. 87 No. 2, pp. 171-178 (1996).
Markie et al., 1993, Somat. Cell Mol. Genet., 19(2):161-169.
Marshall, 1995, Science 269:1050-1055.
Moore et al., 1996, FASEB J., 10(6) Abstract 2725.
Moulard et al., 1994, Eur. J. Biochem. 225:565-572.
Mullen et al., 1994, Plant Physiol., 105:113 (Abstr. 606).
Mulligan, 1993, Science, 260:926-931.
Pachnis et al., 1990, Proc. Natl. Acad. Sci. USA, 87:5109-5113.
Paglia et al., Journal of Experimental Medicine, vol. 183 No. 1, pp. 317-322 (1996).
Peterson et al., 1993, Proc. Natl. Acad. Sci. USA, 90:11207-11211.
Rabinovich et al., 1994, Science, 265:1401-1404.
Sanchez-Pescador et al., 1985, Science, 227:484-492.
Schreuder et al., 1996 Vaccine, 14(5):383-388.
Sousa et al., Journal of Experimental Medicine, vol. 178 No. 2, pp. 509-519 (Aug. 1993).
Stern et al., 1992, Cell, 68:465-477.
Suda et al., 1993, Cell, 75:1169-1178.
Valenzuela et al., 1985 Bio/Technology 3:323-326.
Stubbs et al. “Whole recombinant yeast vaccine activates dendric cells and elicits protective cell-mediated immunity”, Nature Medicine May 2001, vol. 7, pp. 1-5.
International Search Report for International (PCT) Patent Application No. PCT/US03/40281, mailed Sep. 22, 2006.
International Preliminary Examination Report for International (PCT) Patent Application No. PCT/US03/40281, mailed Sep. 22, 2006.
Supplementary European Search Report for European Patent Application No. 03814130.5, dated Apr. 24, 2008.
First Office Action for Chinese Patent Aplication No. 200380109787.5, dated May 23, 2008.
Official Action for U.S. Appl. No. 10/738,646, mailed Jun. 14, 2005.
Official Action for U.S. Appl. No. 10/738,646, mailed Dec. 6, 2005.
Official Action for U.S. Appl. No. 10/738,646, mailed Aug. 29, 2006.
Official Action for U.S. Appl. No. 10/738,646, mailed May 17, 2007.
Official Action for U.S. Appl. No. 10/738,646, mailed Nov. 28, 2007.
Official Action for U.S. Appl. No. 10/738,646, mailed Jul. 1, 2008.
Examiner's First Report for Australian Patent Application No. 2003301021, dated Mar. 12, 2008.
First Examination Report for Indian Patent Application No. 2985/delnp/2005, dated Oct. 12, 2006.
Further Examination Report for Indian Patent Application No. 2985/delnp/2005, dated Sep. 13, 2007.
Translation of Second Office Action for Chinese Patent Application No. 200380109787.5, dated Nov. 28, 2008.
Official Action for U.S. Appl. No. 11/768,144, mailed Oct. 15, 2008.
Marshall et al. “Phase I Study in Cancer Patients of a Replication-Defective Avipox Recombinant Vaccine That Expresses Human Carcinoembryonic Antigen,” Journa

Affiliated with

Also associated with

Rating

Yeast-based vaccines as immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Yeast-based vaccines as immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Yeast-based vaccines as immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4264737